EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKlinische Studie (Phase IV)Open Access · CC BY-NC 4.0

A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan

Masayoshi Harigai iD, Takako Miyamae, Hideyuki Hashimoto, Kosei Umetsu, Katsuhisa Yamashita, Yoshikazu Nakaoka iD

Modern Rheumatology · 06.07.2024 · 34 (4) · 775-783

DOI: 10.1093/mr/road074 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Modern Rheumatology, online erschienen am 31.07.2023. Verfasst von Masayoshi Harigai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Giant Cell Arteritis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

In clinical trials, tocilizumab (TCZ) is efficacious in patients with giant cell arteritis (GCA). This study evaluated the real-world tolerability and effectiveness of TCZ in Japanese patients with GCA.

Methods

In this multicentre, prospective, Phase 4, large-scale, observational study, patients with GCA (with no TCZ treatment 6 months before the study) were recruited from 71 centres across Japan. Patients received subcutaneous TCZ 162 mg weekly (observation period, 52 weeks).

Results

Of the 117 patients [female, 70.1%; mean age, 74.2 years; mean disease duration, 1.4 years; treated for new-onset GCA, 71.8%; presence of large-vessel lesions (LVLs), 61.5%; previous immunosuppressant use, 28.2%; glucocorticoids at baseline, 95.7% (mean: 22.4 mg/day)], 38.5% reported adverse events. The most common adverse events of special interest were neutropaenia and leukopaenia (7.7%), followed by serious infection (6.0%). The relapse-free proportion was 85.0%; relapse after remission, 6.0%; and no remission, 9.0%. At the last observation, 94.2% of relapse-free patients received a concomitant glucocorticoid dose of <10 mg/day. Fatigue, headache, neck pain, and absence of LVLs were positively associated with the relapse.

Conclusions

TCZ was effective and well tolerated in Japanese patients with GCA and may be an effective treatment option combined with glucocorticoids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Giant Cell ArteritisAntibodies, Monoclonal, HumanizedHumansFemaleMaleAgedJapanTreatment OutcomeAged, 80 and overProspective StudiesMiddle AgedGlucocorticoids

Stichwörter der Autor:innen

Giant cell arteritisglucocorticoidslarge-vessel lesionreal-world evidencetocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedGlucocorticoids

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Risk Communication Department, Drug Safety Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
  • Safety Science Department, Drug Safety Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
  • Specialty Medical Science Department, Medical Affairs Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
  • Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.

ORCID-Profile: Masayoshi Harigai, Yoshikazu Nakaoka

Zitieren

APA

Harigai, M., Miyamae, T., Hashimoto, H., Umetsu, K., Yamashita, K., & Nakaoka, Y. (2024). A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan. Modern Rheumatology, 34(4), 775-783. https://doi.org/10.1093/mr/road074

Vancouver

Harigai M, Miyamae T, Hashimoto H, Umetsu K, Yamashita K, Nakaoka Y. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan. Modern Rheumatology. 2024;34(4):775-783. doi:10.1093/mr/road074

BibTeX
@article{Harigai2024,
  author = {Harigai, Masayoshi and Miyamae, Takako and Hashimoto, Hideyuki and Umetsu, Kosei and Yamashita, Katsuhisa and Nakaoka, Yoshikazu},
  title = {A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan},
  journal = {Modern Rheumatology},
  year = {2024},
  volume = {34},
  number = {4},
  pages = {775--783},
  doi = {10.1093/mr/road074}
}
Kostenlos starten →